Research ArticleBIOCHEMISTRY

Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features

Science Advances  09 Sep 2016:
Vol. 2, no. 9, e1601017
DOI: 10.1126/sciadv.1601017

You are currently viewing the abstract.

View Full Text


Because of its involvement in the progression of several malignant tumors, the histone lysine-specific demethylase 1 (LSD1) has become a prominent drug target in modern medicinal chemistry research. We report on the discovery of two classes of noncovalent inhibitors displaying unique structural features. The antibiotics polymyxins bind at the entrance of the substrate cleft, where their highly charged cyclic moiety interacts with a cluster of positively charged amino acids. The same site is occupied by quinazoline-based compounds, which were found to inhibit the enzyme through a most peculiar mode because they form a pile of five to seven molecules that obstruct access to the active center. These data significantly indicate unpredictable strategies for the development of epigenetic inhibitors.

  • LSD1
  • quinazoline
  • polymyxin
  • histone demethylation
  • reversible inhibition

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

View Full Text

More Like This